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Abstract
Background: Previous trials of the RTS, S malaria candidate vaccine have shown that this vaccine is safe, tolerated and
immunogenic. The development plan for this vaccine aims at administering it in the first year of life through the Expanded
Program on Immunization (EPI). The objective was to evaluate the safety and reactogenicity of RTS, S/AS02D (0.5 ml
dose), a pediatric formulation of GlaxoSmithKline Biologicals' current malaria candidate vaccine RTS, S/AS02A (0.25 ml
dose). A 0.5 ml dose of AS02D is composed of the same active ingredients in the same quantities as in a 0.25 ml dose of
AS02A and has been developed to be easily introduced into routine EPI practices.
Methods:  We performed a phase I/IIb randomized double-blind bridging study in a malaria-endemic region of
Mozambique, to compare the safety and immunogenicity of both candidate vaccines with the aim of replacing RTS, S/
AS02A with RTS, S/AS02D as the candidate pediatric vaccine. 200 Mozambican children aged 3 to 5 years were
randomized 1:1 to receive one of the 2 vaccines according to a 0, 1, 2 month schedule.
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Results: Both vaccines were safe and had similar reactogenicity profiles. All subjects with paired pre and post-vaccination
samples showed a vaccine response with respect to anti-circumsporozoite (CS) antibodies irrespective of initial anti-CS
serostatus. Geometric mean titers (GMTs) were 191 EU/ml (95% CI 150–242) in recipients of RTS, S/AS02D compared
to 180 EU/ml (95% CI 146–221) in recipients of RTS, S/AS02A. For the anti-hepatitis B surface antigen (HBsAg), all
subjects were seroprotected at day 90, and the GMTs were 23978 mIU/ml (95% CI 17896–32127) in RTS, S/AS02D
recipients and 17410 mIU/ml (95% CI 13322–22752) in RTS, S/AS02A recipients. There was a decrease in anti-CS GMTs
between months 3 and 14 in both groups (191 vs 22 EU/mL in RTS, S/AS02D group and 180 vs 29 EU/mL in RTS, S/
AS02A group).
Conclusion: Our data show that the RTS, S/AS02D is safe, well tolerated, and demonstrates non-inferiority (defined as
upper limit of the 95% confidence interval of the anti-CS GMT ratio of RTS, S/AS02A to RTS, S/AS02D below 3.0) of the
antibody responses to circumsporozoite and HBsAg induced by the RTS, S/AS02D as compared to the RTS, S/AS02A.
Background
Malaria is still leading the list of killer diseases in Africa.
Two million children die annually from this disease [1,2]
primarily due to infection with Plasmodium falciparum.
Currently, malaria control strategies are chiefly based on
the early diagnosis and treatment of infected individuals.
While preventive measures such as vector control and
insecticide treated bednets remain indispensable, a vac-
cine is viewed as an essential part of the long-term strategy
to control malaria, especially in Africa, where ninety per
cent of all deaths due to malaria occur.
More than 50 candidate vaccines are currently under
development [3,4]. GlaxoSmithKline (GSK) Biologicals
has developed in collaboration with the Walter Reed
Army Institute of Research an adjuvanted candidate
malaria vaccine, based on the RTS, S antigen. Since 2001,
trials of this vaccine in children have been conducted
under a partnership agreement between GSK and the
PATH Malaria Vaccine Initiative (MVI). The goal of this
partnership is to develop the vaccine for the routine
immunization of infants and children living in malaria
endemic regions of Africa.
The RTS, S candidate vaccine consists of sequences of the
circumsporozoite (CS) protein and the hepatitis B surface
antigen (HBsAg) (RTS, S) formulated with AS02 (proprie-
tary oil in water emulsion, MPL® and QS21 immunostim-
ulants). Adjuvanted vaccines based on RTS, S would
potentially offer protection against malaria disease due to
P. falciparum. In addition, studies with the RTS, S/AS02A
candidate in African children have shown that the vaccine
stimulates the production of high anti-HBsAg antibody
titers [5-7].
Previous trials have shown that this vaccine is safe, well
tolerated, and immunogenic in malaria-naive [8], semi-
immune adults [9], in children aged 6 to 11 years and 1 to
5 years in the Gambia [5]. Safety and proof-of-concept of
efficacy were demonstrated in clinical trials conducted in
children aged 1 to 4 years in Mozambique [6,7].
Trials of RTS, S candidate vaccine in children under the
age of 6 years have most commonly used a fractional dose
of the 0.5 ml adult formulation of the RTS, S/AS02A vac-
cine. An aim of the development plan for this candidate
vaccine is to administer it in the first year of life with other
vaccines given as part of the Expanded Program on Immu-
nization (EPI) of the World Health Organization (WHO).
Currently most injected vaccines given as part of the EPI
schedule are administered at a dose volume of 0.5 ml.
This study compared the previously tested RTS, S/AS02A
vaccine with a new formulation RTS, S/AS02D. A 0.5 ml
dose of RTS, S/AS02D is composed of the same active con-
stituents as in a 0.25 ml dose of RTS, S/AS02A, but the
final volume has been adjusted to be compatible with the
auto-disable syringes used in the EPI program. This trial
serves as a clinical bridge of the new EPI-compatible for-
mulation RTS, S/AS02D to the formulation that has dem-
onstrated efficacy in Mozambican children RTS, S/AS02A.
Methods
Study area
The study was conducted at the Centro de Investigação em
Saúde de Manhiça (Manhiça Health Research Centre –
CISM), in the Manhiça district (capital Manhiça, 25°24' S,
32°48' E, 50.5 m above sea level), in southern Mozam-
bique. Manhiça lies 80 km north of the Mozambican cap-
ital Maputo. The area is a flat savannah with two distinct
seasons: a warm season between November and April,
when most of the rains occur, and a cool and generally dry
season during the rest of the year. The average annual rain-
fall is 1100 mm. Moderately intense malaria transmis-
sion, mainly caused by P. falciparum, is perennial and
marked by substantial seasonality [10]. The estimated
average Entomological inoculation rate (EIR) is 38 infec-
tive bites per person per year, and Anopheles funestus is the
main vector [6].
The CISM is the first peripheral research centre of the
Mozambican Ministry of Health and is adjacent to the
Manhiça Hospital. A continuous Demographic Surveil-
lance System has been set up since mid-1996 in an area ofTrials 2007, 8:11 http://www.trialsjournal.com/content/8/1/11
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approximately 10 km around the centre, referred to as the
study area, where participants to this study were recruited.
Currently the study area covers 500 km2 and 70,000
inhabitants.
The Manhiça Hospital is a referral health facility for the
Manhiça district. It has a 110-bed inpatient ward, an out-
patient department, a maternal and child health clinic
and an emergency room. Malaria, acute respiratory infec-
tion, and malnutrition remain the most important causes
of illness and death in children < 5 years old. Currently it
also carries out preventive and treatment programs for
HIV/AIDS. The district health network consists of a further
eight peripheral health posts and a rural hospital. Addi-
tional information on the area can be found elsewhere
[6,11].
Study population
In this phase I/IIb study, 200 healthy children aged 3 to 5
years were recruited into two equal groups at a single cen-
tre in Mozambique. Non-coercive methods were used
during the recruitment. The protocol was approved by the
national Mozambican ethics review committee; the Hos-
pital Clinic of Barcelona ethics review committee, and the
Human Subjects Protection Committee of PATH. The trial
was undertaken according to the International Confer-
ence on Harmonization Good Clinical Practice guidelines
and was monitored by GSK Biologicals. A Local Safety
Monitor and a formally constituted Data Safety Monitor-
ing Board (DSMB) operating under a charter, closely
reviewed the conduct and results of the trial.
The selection of the potential candidates was based on the
demographic surveillance system in place in the study
area, covering a population of around 70 000 people. Lists
of potentially eligible resident children were produced
from this census. Prior to the enrolment, information
sheets and invitations to participate in the trial were deliv-
ered and read to parents and guardians of these children.
The information sheets were in Portuguese or the local
language (Shangana or Ronga). Criteria for recruitment
included confirmed residency in the study area and full
immunisation with EPI vaccines as indicated on the
child's health card. Only children whose parents or guard-
ians had signed or thumb-printed a consent document
were screened for eligibility into the study. Standard inclu-
sion and exclusion criteria were checked. At screening, a
brief medical history and a medical examination of each
child were performed. Blood samples were taken by finger
prick for hematology and biochemistry tests. On the day
of first vaccination, children were randomized in a 1:1
fashion to receive three doses of either RTS, S/AS02A can-
didate malaria vaccine or RTS, S/AS02D (GlaxoSmithK-
line Biologicals, Rixensart, Belgium) according to a 0, 1, 2
months vaccination schedule.
The candidate vaccine was administered in a double-blind
manner (observer blinded, participant blinded). Details
about study design are presented in Figure 1.
Vaccines
The RTS, S/AS02A vaccine
The RTS, S antigen was presented as lyophilized antigen
pellet containing 62.5 μg of RTS, S with 12.6 mg of
sucrose as cryoprotectant per 3 mL monodose vial. The
pellet was reconstituted with adjuvant in liquid form and
0.5 mL of reconstituted vaccine contains 50 μg RTS, S.
The adjuvant AS02A contains 50 μg MPL®, 50 μg QS-21
(QS21 is a triterpene glycoside purified from the bark of
Quillaja saponaria) and 250 μl of a proprietary oil-in-
water-emulsion in phosphate buffered saline per 0.5 mL,
presented in prefilled syringes (PFS). In this study a final
dose volume of 0.25 mL of the vaccine, was administered.
RTS, S/AS02D vaccine
The RTS, S antigen was presented as lyophilized antigen
pellet contains 31.25 μg of RTS, S with 12.6 mg of sucrose
as cryoprotectant per 3 mL monodose vial. The pellet was
reconstituted with adjuvant in liquid form and 0.5 mL of
reconstituted vaccine contains 25 μg RTS, S. The AS02D
contains 25 μg of MPL®, 25 μg QS21 (QS21 is a triterpene
glycoside purified from the bark of Quillaja saponaria) and
125 μl of a proprietary oil-in-water emulsion in phos-
phate buffered saline per 0.5 mL, presented in prefilled
syringes. A dose of 0.5 mL was delivered.
The RTS, S/AS02A (0.25 mL dose) was supplied such that
the reconstituted vaccine provided a 0.5 mL volume. One
0.25 mL dose was aspirated from each vial and used. The
RTS, S/AS02D (0.5 mL dose) was supplied such that the
reconstituted vaccine volume provided a 0.5 mL pediatric
dose. One 0.5 mL dose was aspirated from each vial and
used. Both vaccines had the same aspect, which was an
opaque milky liquid.
Assessment of safety and reactogenicity
Safety was assessed by the measurement of hematological
and biochemical parameters and the recording of solicited
local and general symptoms during a 7-day follow-up
period after each vaccination, and of unsolicited non-seri-
ous adverse events (AE) in the 30 days post-vaccination, as
well as any serious adverse event (SAE) occurring through-
out the study.
Blood samples were taken by finger prick at screening one
month after the first and last doses and at the end of study
follow-up (month 14), for the assessment of safety
parameters (complete blood count, hematocrit, creati-
nine, ALT and bilirubin), and also for testing for HBsAg at
screening. HBsAg testing was carried out at the Microbiol-Trials 2007, 8:11 http://www.trialsjournal.com/content/8/1/11
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ogy Service of the Hospital Clínic in Barcelona, using a test
kit (ETI-MAK-4 DIASORIN or equivalent) according to
the manufacturer's instructions and laboratory SOPs.
Local symptoms included pain or swelling at the injection
site, and general symptoms included fever (defined as
axillary temperature ≥ 37.5°C, taken by the field worker),
drowsiness, loss of appetite and irritability or fussiness.
Grade 3 fever was defined as axillary temperature >
39.0°C. Grade 3 pain was defined as crying when the limb
was moved or spontaneously painful limb; grade 3 fussi-
ness as crying that could not be comforted or fussiness
that prevented normal activity; grade 3 loss of appetite as
not eating at all, and for all other symptoms, grade 3
intensity was defined as preventing normal everyday activ-
ities.
Trained field workers, under the supervision of the Princi-
pal Investigator, visited each enrolled subject at daily
intervals for days 1 to 6 after each vaccination. If the field
worker found any grade 3 solicited general or unsolicited
symptoms, the volunteer was brought to the Manhiça
Hospital for examination by the Principal Investigator or
other designated staff member. Any further clinical data,
including the treatment provided, were written on diary
cards and clinic forms and transcribed on to the Case
Report Forms. If the physician found that the child had
experienced an SAE, GSK Biologicals, MVI, and the Local
Safety Monitor were promptly notified.
Assessment of immunogenicity
Immunogenicity was assessed through the determination
of blood parameters. Blood samples were taken by finger
prick prior to the first dose (day 0), at month 3 and 14 for
anti-HBsAg and anti-CS antibodies measurement.
Anti-HBsAg antibodies were tested at GSK Biologicals,
Rixensart, Belgium, using an AUSAB EIA, Abbott, which
had a cut-off of 10 mIU/ml. Antibodies specific for the cir-
cumsporozoite protein tandem repeat epitope were
assessed by a standard, validated ELISA with plates
adsorbed with the recombinant antigen R32LR that con-
tains the sequence [NVDP(NANP)15]2LR. Briefly, R32LR
protein was coated onto a 96-well polystyrene plate.
Serum samples serial dilutions were added directly to the
plate. The plates were washed and polyclonal rabbit anti-
human IgG/HRP was added. After a final washing step
and a color reaction with 3, 3',5,5' tetramethylbenzidine,
Overall Study Design Figure 1
Overall Study Design. Key: Vacc: Vaccination; FP: Fingerprick; BS: Bloodsample.Trials 2007, 8:11 http://www.trialsjournal.com/content/8/1/11
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the plates were read in an ELISA reader. The titers were cal-
culated from a standard curve with the software Softmax-
Pro (using a four parameters equation) and expressed as
EU/ml. Anti-CS antibodies were tested at the CEVAC Lab-
oratory, University of Ghent, Belgium. The cut-off for the
anti-CS ELISA was 0.5 EU/ml.
Statistical methods
Sample size calculation
Seventy-two evaluable subjects per group were required to
demonstrate non-inferiority of RTS, S/AS02D compared
to RTS, S/AS02A with 95% power, by comparing the
upper limit of the 95% CI of the ratio of anti-CS GMTs
(RTS, S/AS02A : RTS, S/AS02D) with a non-inferiority
limit set at 3, assuming a log standard deviation of anti-CS
GMTs of 0.72 (MAL-025; GSK data on file). Allowing for
a chronic carriage rate of Hepatitis B virus of 15% and a
drop out rate of 15%, it was necessary to enroll approxi-
mately 100 children per arm in this study.
Datasets used
Safety and reactogenicity were analyzed using the total
cohort, defined as all enrolled subjects for whom safety
and reactogenicity data were available. Immunogenicity
was analyzed using the according to protocol (ATP)
cohort, defined as all evaluable subjects (i.e. those meet-
ing all eligibility criteria, complying with the procedures
defined in the protocol, with no elimination criteria dur-
ing the study) who tested negative for HBsAg at screening
and for whom data concerning immunogenicity endpoint
measures were available. These included subjects for
whom assay results were available for antibodies against
at least one study vaccine antigen component after Dose
3.
Analysis of immunogenicity
For each group, the seropositivity rate for anti-CS antibod-
ies (proportion of subjects with anti-CS antibody titers of
≥ 0.5 EU/ml), and the seroprotection rate for anti-HBsAg
antibodies (proportion of subjects with anti-HBsAg anti-
body titers of ≥ 10 mIU/ml) and their 95% Confidence
Intervals (CI) were tabulated by vaccine dose at each time
point (day 0 and months 3 and 14). Geometric mean tit-
ers (GMTs) for anti-CS antibodies (EU/ml), and anti-
HBsAg antibodies (mIU/ml) with 95% CI were calculated
for each group at each time point when a serology sample
was taken.
The anti-CS vaccine response was calculated in two ways;
the percentage of subjects with 3-fold increase in titers
between day 0 and month 3 (day 90) and the geometric
mean ratio (GMR, ratio of geometric means), which was
the fold increase in antibody GMTs at day 90 compared to
day 0.
In order to demonstrate non-inferiority for anti-CS and
anti-HBsAg antibodies, the 95% CI for the ratio of GMTs
(RTS, S/AS02A [0.25 ml dose] to RTS, S/AS02D [0.5 ml
dose]) was computed using a one-way ANOVA model on
the logarithm10 transformation of the titers. The 95% CI
was also calculated using an analysis of covariance
(ANCOVA) when adjusting for pre-vaccination titers. If
the upper limit of the 95% confidence intervals of the
ratio was below the clinical limits defining non-inferiority
(three-fold difference), we can conclude that RTS, S/
AS02D (0.5 ml dose) was non-inferior as compared to
RTS, S/AS02A (0.25 ml dose).
Analysis of safety and reactogenicity
The percentage of subjects reporting solicited AEs within
the seven-day follow-up period after vaccination was cal-
culated with exact 95% CI by vaccine group, according to
the type of AE (any and each specific solicited AE), their
intensity (any and grade 3 only) and for general AE,
according to their relationship to vaccination (any and
those with suspected or probable relationship to vaccina-
tion). The percentage of subjects with any or related unso-
licited symptom reported up to 30 days after vaccination,
as tabulated per group. All serious adverse events occur-
ring up to 30 days after dose three were listed for each
treatment group.
Results
A total of 200 children (100 per group), aged between 3
and 5 years were enrolled in this 14-month study from
March 2004 to April 2005. The two groups were compara-
ble with respect to mean age, sex and race (Table 1). Six
subjects dropped out from the double-blind phase (day 0
to end of Month 3) and therefore, 194 subjects (97 per
group) participated in the single-blind phase of the study
(Month 4 to Month 14). Of the 194 subjects enrolled in
the single-blind phase study, 165 subjects completed the
study (81 in the RTS, S/AS02D group and 84 in the RTS,
S/AS02A group). The reasons for withdrawal for the 29
subjects (16 in the RTS, S/AS02D group and 13 in the RTS,
S/AS02A group) are presented in the (Figure 2).
Safety and reactogenicity
The incidence of symptoms, local and general solicited
symptoms were not statistically different between the two
groups (Table 2). The most frequently reported local
symptom was pain, reported by 35% and 45% of subjects
in the RTS, S/AS02D and RTS, S/AS02A groups respec-
tively. The most frequently reported general symptom was
irritability, reported by 28% and 25% of subjects in the
two groups respectively. The incidence of symptoms in
the seven days following vaccination did not increase with
subsequent vaccinations in either group (data not
shown). Grade 3 symptoms were reported with similar
frequency in both groups.Trials 2007, 8:11 http://www.trialsjournal.com/content/8/1/11
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The number of subjects with at least one unsolicited
symptom reported during the 30-day follow-up and deter-
mined by the investigator to be related to vaccination was
low (1.0% in the RTS, S/AS02D group vs 0% in the com-
parator group). We reported one SAE in the double-blind
phase (RTS, S/AS02A group) and 10 (six in RTS, S/AS02D
group and four in RTS, S/AS02A group) during the single-
blind phase. None of the reported SAEs were considered
to be causally related to vaccination. One volunteer that
developed AIDS died during the follow-up period.
Immunogenicity
One month following the last dose of vaccine (day 90), all
subjects included in the ATP analysis of immunogenicity
were seropositive with respect to anti-CS antibodies
(Table 3). All subjects with paired pre- and post-vaccina-
tion samples showed a vaccine response with respect to
anti-CS. GMTs were 191 EU/ml (95% CI 150–242) in
recipients of RTS, S/AS02D compared to 180 EU/ml (95%
CI 146–221) in recipients of RTS, S/AS02A. The RTS, S/
AS02A:RTS, S/AS02D GMT ratio was 0.9 (95% CI 0.7–
1.3). As the upper limit of the 95% CI of the GMT ratio
between groups was below the pre-defined limit for non-
inferiority of three (Table 3), non-inferiority of RTS, S/
AS02D compared to RTS, S/AS02A was demonstrated in
terms of the response to CS, and the primary objective was
met. There was a decrease in anti-CS GMTs between
month 4 and month 14 in both groups (191 vs 22 EU/ml
and 180 vs 29 EU/ml in the RTS, S/AS02D and RTS, S/
AS02A groups, respectively).
With respect to anti-HBsAg, all subjects were seropro-
tected at day 90 (Table 3), and the GMTs were 23978
mIU/ml (95% CI 17896 – 32127) in RTS, S/AS02D recip-
ients and 17410 mIU/ml (95% CI 13322–22752) in RTS,
S/AS02A recipients. The RTS, S/AS02A:RTS, S/AS02D
Table 1: Summary of demographic characteristics (Total cohort)
Characteristics Parameters 
or 
Categories
RTS, S/AS02D N = 100 RTS, S/AS02A N = 100 Total N = 200
Value or n % Value or n % Value or n %
Age (years) (at the start of the single-blind phase) Mean 4.2 - 4.2 - 4.2 -
SD 0.99 - 0.89 - 0.94 -
Median 4.0 - 4.0 - 4.0 -
Minimum 3 - 3 - 3 -
Maximum 6 - 6 - 6 -
Unknown 3 - 3 - 6 -
Gender Female 46 46.0 57 57.0 103 51.5
Male 54 54.0 43 43.0 97 48.5
Race Black 100 100.0 100 100.0 200 100.0
Height (cm) Mean 99.5 - 99.9 - 99.7 -
SD 7.26 - 7.26 - 7.24 -
Median 99.5 - 101.0 - 100.0 -
Weight (kg) Mean 15.4 - 15.8 - 15.6 -
SD 2.44 - 2.51 - 2.48 -
Median 15.4 - 15.8 - 15.6 -
BMI (kg/m2) Mean 15.5 - 15.9 - 15.7 -
SD 1.37 - 1.87 - 1.64 -
Median 15.6 - 15.5 - 15.5 -
N: total number of subjects
n (%): number (percentage) of subjects in a given category
Value: value of the considered parameter
SD: standard deviation
BMI: Body Mass Index (kg/m2) = Weight/Height2Trials 2007, 8:11 http://www.trialsjournal.com/content/8/1/11
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Trial profile Figure 2
Trial profile. QNS: Quantity not sufficient.Trials 2007, 8:11 http://www.trialsjournal.com/content/8/1/11
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GMT ratio was 0.7 (95% CI 0.5–1.1). As the clinical limit
defining non-inferiority was defined as an upper limit of
the 95% CI of 3, non-inferiority was concluded.
Discussion
In most areas of stable malaria transmission in Africa, the
prevalence of infection increases over the first few years of
life and classically peaks around 5 years of age. This has
led to the long term notion that immunity against the par-
asite tends to develop slowly, and that the main burden of
malaria is in children around that age. However, emerging
evidence shows that, a very significant proportion of
deaths and severe episodes due to P. falciparum malaria
concentrate in children less than 18 months of age
[10,12]. Any control tool that aims towards having a sig-
nificant public health impact should therefore be deliv-
ered as early as possible in life so as to prevent the
significant morbidity and mortality associated with P. fal-
ciparum infection during the first 18 months.
Many African countries where malaria is endemic struggle
with limited human and financial resources to run effi-
cient National Health Services (NHS). The Ministry of
Health of Mozambique estimates that approximately 50%
of its population has no access to the services of its NHS.
This rather common fact reminds us of the limitations of
treatment of malaria cases and emphasizes the need to
deploy preventive tools. One relatively well-functioning
health service operating in developing countries is the
WHO EPI, which manages to deliver a number of different
vaccines, even to remote populations, during the first year
of life. Renewed efforts to strengthen this system through
GAVI/The Vaccine Fund, are yielding significant results
with respect to vaccine delivery and the attainment of high
coverage rates. Taking into consideration these elements,
the Clinical Development Plan (CDP) of RTS, S malaria
vaccine for public health use in Africa, aims to deliver vac-
cines as early as possible in life to prevent mortality due to
malaria during the first months of life. Furthermore, the
Table 2: Overall incidence of solicited or unsolicited symptoms and incidence of individual solicited symptoms (any intensity and grade 
3) in the 7-day follow-up period after vaccination (Total cohort)
Group RTS, S/AS02D (N = 100) RTS, S/AS02A (N = 100)
% 95% CI % 95% CI
Any symptoms* 64.0 (53.8;73.4) 72.0 (62.1; 80.5)
Grade 3 10.0 (4.9 ; 17.6) 13.0 (7.1; 21.2)
General symptoms* 43.0 (33.1; 53.3) 42.0 (32.2; 52.3)
Grade 3 7.0 (2.9 ;13.9) 8.0 (3.5; 15.2)
Local symptoms* 39.0 (29.4;49.3) 55.0 (44.7; 65.0)
Grade 3 3.0 (0.6; 8.5) 5.0 (1.6; 11.3)
Pain Any 35.0 (25.7; 45.2) 45.0 (35.0; 55.3)
Grade 3 2.0 (0.2; 7.0) 1.0 (0.0; 5.4)
Swelling Any 9.0 (4.2; 16.4) 23.0 (15.2; 32.5)
Grade 3 1.0 (0.0; 5.4) 4.0 (1.1; 9.9)
Drowsiness Any 12.0 (6.4; 20.0) 8.0 (3.5; 15.2)
Grade 3 4.0 (1.1; 9.9) 3.0 (0.6; 8.5)
Fever Any 2.0 (0.2; 7.0) 1.0 (0.0; 5.4)
Grade 3 0.0 (0.0; 3.6) 0.0 (0.0; 3.6)
Irritability Any 28.0 (19.5; 37.9) 25.0 (16.9; 34.7)
Grade 3 11.0 (5.6; 18.8) 10.0 (4.9; 17.6)
Loss of Appetite Any 6.0 (2.2; 12.6) 3.0 (0.6; 8.5)
Grade 3 1.0 (0.0; 5.4) 1.0 (0.0; 5.4)
N = number of subjects having received at least one dose and included in the analysis of reactogenicity
N (%) = number (percentage) of subjects presenting at least one type of symptom during the 7 day follow-up period after vaccination (day 0 to day 
6)
*Any/General/Local symptom = includes all/general/local solicited and unsolicited symptoms occurring during the 7-day post vaccination follow-up 
periodTrials 2007, 8:11 http://www.trialsjournal.com/content/8/1/11
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CDP ideally aims to deliver a malaria vaccine alongside
other vaccines within the EPI schedule, thereby making
use of already existing contacts between the health serv-
ices and the target population.
RTS, S/AS02D, a new formulation of the RTS, S candidate
malaria vaccine, has been produced in order to match the
volume of all other vaccines administered during the first
year of life and therefore facilitate its administration and
inclusion into the EPI schedule.
This study shows that the safety and reactogenicity profile
observed with RTS, S/AS02D is similar to that of RTS, S/
AS02A, as well as that previously documented in other
studies for RTS, S/AS02A [5]. Although there are no estab-
lished immune correlates of protection against malaria
sporozoites and liver stage parasite, it is widely believed,
on the basis of preclinical studies in animal models and
clinical investigators, that both humoral and cell-medi-
ated immune responses are involved in protective immu-
nity [13,14]. In this trial conducted in African children we
were not able to adequately measure T-cell immunity.
Humoral responses were therefore used as the best availa-
ble and relevant tool for this clinical bridge between the
two formulations of RTS, S. Using this analysis, the study
shows that the immunogenicity of the two formulations
are similar, for both anti-CS and anti-HBsAg humoral
responses. This result allows us to proceed with the CDP,
caring studies in infancies in parallel with the EPI immu-
nization. Some of these studies are now ongoing.
Conclusion
In conclusion, our data show that the new formulation,
RTS, S/AS02D (0.5ml) is as safe and immunogenic as the
existing formulation, RTS, S/AS02A (0.25 ml), in this
Mozambican pediatric population. These results allow us
to proceed further in the clinical development of this can-
didate malaria vaccine and initiate Phase I/IIb trials in the
infant population.
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